Braveheart
braveheart.bio
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$185M
1 round on record
Latest round
$185M
Venture round · Nov 2025 · 10 mo ago
Team
11-50
employees, estimated range
Backers
2
OrbiMed, Valueaddvc
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Nov 5, 2025
Raised a round Venture round $185M · YahooFinance
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Nov 2025 | $185M | — | YahooFinance |
Backed byfrom the funds' portfolios and accelerator catalogs
OrbiMed 
Valueaddvc Similar startupsby what they do, their industry and backers
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
AER Therapeutics is developing mucolytic treatments that target mucus plugs in COPD and asthma to improve lung function and quality of life.
-Our Mission 誰もが空の恩恵を享受できる世界を実現する トラジェクトリーは、管制の自動化を通じて、誰もが安全かつ簡単に無人航空機の恩恵を享受できる社会を実現し、人々のQOL（Quality of Life）の向上に貢献するというミッションを掲げています。.
Our mission is to improve the quality of life of patients with myocardial infarction (MI) and heart failure by providing novel…
SignaCor, a UK based, clinical stage biotech company are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic…
Medical Device Developmentto Enhance the Quality of Life. 再生医療機器開発.
News
Braveheart Bio Shares Climb 5.50% as Its Phase 3 Heart Drug Trial Rapidly Gains Momentum Following Its IPO
Braveheart Bio shares rose 5.5% after the company began its pivotal Phase 3 trial of BHB-1893 and reported financial results supporting development of two late-stage programmes.
Read more
Report
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) InitiatedCash and Cash Equivalents of $122.8 Million as ...
Read more
Report
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart Bio
Read more
Report
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
--Braveheart Bio, Inc., a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases, today reported unaudited financial results for the second quarter ended J
Read more
Report
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Option exercise expands executive
Read more
Report
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Option exercise expands executive's long-term equity stake to 612,251 shares, now valued at $18.37 million based on August 7 market close.
Read more
Report
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Motley Fool Press Release.
Read more
Report
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
Results with next-generation cardiac myosin inhibitor suggest a potentially disease-modifying therapy in non-obstructive hypertrophic cardiomyopathy...
Read more
Report
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of use, including simplified dosing regimen...
Read more
Report
Show more news
Financials
Total raised
$185M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2025 | $185M | Details |